Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling

Figure 3

Abrine stimulates activation and function of T cells. (a–c) The unstimulated or activated PBMCs were set in top chambers of the Transwell; the liver cancer cells were placed in the bottom chambers. The level of PD-L1 in HepG2 cells (a) and percentage of CD4+/PD-1+ T cells (b) and CD8+/PD-1+ T cells (c) were checked by flow cytometry. (d) The PD-L1 level of HepG2 cells under treatment with conditioned medium of PBMCs detected by flow cytometry. (e) T cell proliferation under coculture with HepG2 and Huh7 cells was determined by CCK-8 assay. (f) T cell activity under con-culture with HepG2 and Huh7 cells was measured by flow cytometry detection of CD8+ T cells. (g) Apoptosis of T cells were determined by flow cytometry. vs. control.

(a)

(b)

(c)

(d)

(e)

(f)

(g)